BC Innovations | Oct 7, 2019
Distillery Therapeutics

Bispecific cytokine fusion for Type II diabetes

DISEASE CATEGORY: Endocrine/metabolic disease INDICATION: Diabetes A chimeric protein derived from two cytokines previously shown to modify food intake, IL-6 and CNTF, could treat Type II diabetes. The chimeric cytokine is based on IL-6, with...
BC Innovations | Aug 8, 2019
Distillery Therapeutics

LIF-expressing myeloid cells for DMD

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy LIF-expressing myeloid cells could help treat Duchenne muscular dystrophy (DMD). Bone-marrow derived macrophages, which infiltrate dystrophic muscle tissue, isolated from mice overexpressing human LIF in myeloid cells exhibited lower...
BC Innovations | Aug 8, 2019
Distillery Therapeutics

LIF inhibition sensitizes pancreatic cancer to chemotherapy

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inhibiting LIF could sensitize KRAS-driven pancreatic cancer to chemotherapy. LIF levels were higher in two human pancreatic ductal adenocarcinoma (PDAC) cell lines with KRAS-activating mutations than in a cell...
BC Extra | Apr 17, 2019
Preclinical News

Salk study unveils LIF's mechanism in form of pancreatic cancer

A new study from Salk Institute for Biological Studies pinpoints new mechanistic details about how LIF promotes pancreatic cancer, providing preclinical support for Northern Biologics' lead candidate. In a Nature paper published Wednesday, Salk's Tony...
BC Innovations | Oct 31, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Blindness Mouse studies identified a LIF-based fusion protein that could help treat blindness. The fusion protein consists of human LIF fused to bacterial dihydrofolate reductase (DHFR), which is stabilized by the antibiotic Primsol trimethoprim....
BioCentury | Jan 27, 2018

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
BC Extra | Nov 9, 2017
Company News

Vickers to helm Northern Biologics

Northern Biologics Inc. (Toronto, Ontario) announced Thursday that Phil Vickers will join the company as CEO. Vickers departed as global head of R&D of Shire plc (LSE:SHP; NASDAQ:SHPG) in June (see BioCentury Extra, June 30)...
BC Extra | Oct 27, 2017
Preclinical News

Syros, UCSD team identifies pancreatic cancer targets

Researchers from Syros Pharmaceuticals Inc. (NASDAQ:SYRS) and the University of California San Diego identified targets for pancreatic cancer by using Syros' gene control platform to analyze super-enhancers -- "master switch" transcriptional regulators responsible for maintaining...
BC Innovations | Oct 26, 2017
Tools & Techniques

Ripe for enhancement

Although still largely the purview of academics, technologies for mapping enhancers to the genes they control are rapidly gaining efficiency and promise to unlock a trove of new targets for drug developers. But companies will...
BC Innovations | Sep 21, 2017
Emerging Company Profile

Two leases on LIF

While most immuno-oncology products in the clinic target the immunosuppressive factors that help tumors evade an attack, Northern Biologics Inc. 's anti- LIF antibody takes a step further. By simultaneously blocking both immunosuppression and self-renewal...
Items per page:
1 - 10 of 48